Tekmira Pharmaceuticals Corp (TKMR) 18.75 $TKMR
Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results
GlobeNewswire - Wed Apr 22, 6:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), announced that it will hold a conference call and webcast on Wednesday, May 6, 2015 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and first quarter financial results.
TKMR: 18.75 (-0.25)
Tekmira Pharmaceuticals'
at Investor's Business Daily - Wed Apr 22, 5:48PM CDT
Tekmira Pharmaceuticals' (TKMR) Ebola-fighting drug, in a recent test, cured 3 monkeys infected with the strain of the virus that has devastated W. Africa over the past year, Reuters reported. Shares fell 0.8% to 18.38.
TKMR: 18.75 (-0.25)
Tekmira and Collaborators Publish Positive Preclinical Ebola Survival Data in Nature Journal
GlobeNewswire - Wed Apr 22, 1:13PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today the publication of preclinical data highlighting positive results against Ebola virus Makona infection using a newly adjusted siRNA cocktail. The paper is titled, "Lipid Nanoparticle siRNA Treatment of Ebola Virus Makona-infected Nonhuman Primates," (Thi et al., Nature April 22, 2015, doi:10.1038/nature14442).
TKMR: 18.75 (-0.25)
Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 15, 2:15PM CDT
The Medicines Co. (MDCO) was in the limelight with the company gearing up for an FDA advisory panel meeting.
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), GWPH: 121.00 (+0.23), MDCO: 27.41 (+0.09), ALXN: 180.08 (-4.50), TKMR: 18.75 (-0.25), AMGN: 167.91 (-1.26)
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 10:10AM CDT
The FDA has notified Tekmira (TKMR) that it has modified the partial clinical hold on the IND for TKM-Ebola.
SRPT: 13.42 (-0.24), TKMR: 18.75 (-0.25), GSK: 46.59 (+0.28), ACOR: 33.12 (-0.38)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Tekmira will resume safety study of Ebola drug within weeks
AP - Fri Apr 10, 10:46AM CDT
NEW YORK (AP) — Canadian drugmaker Tekmira Pharmaceuticals said Friday it will restart a study of an experimental Ebola treatment in the coming weeks.
TKMR: 18.75 (-0.25), TKM.TO: 22.97 (+0.52)
Tekmira's Ebola vaccine candidate cleared for repeat dosing in Phase 1 study
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 8:45AM CDT
TKMR: 18.75 (-0.25)
FDA Modifies Partial Clinical Hold on Tekmira's TKM-Ebola IND to Allow Multiple Dosing of Healthy Volunteers
GlobeNewswire - Fri Apr 10, 7:30AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that the partial clinical hold on the company's Investigational New Drug application (IND) for TKM-Ebola has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day. The IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers.
TKMR: 18.75 (-0.25)
Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride Lowering by Silencing of ApoC3 and ANGPTL3 Genes
GlobeNewswire - Wed Mar 25, 6:30PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that new preclinical data on TKM-HTG, an RNAi therapeutic, were presented at the Keystone Symposia Conference: Liver Metabolism and Nonalchoholic Fatty Liver Diseases, in Whistler, Canada, March 22-27, 2015. Dr. Narayanan Hariharan, Senior Director of Research for Tekmira, delivered a podium presentation at the conference titled, "Novel RNAi-Lipid Nanoparticle Therapeutics for Hypertriglyceridemia," and a poster presentation titled, "TKM-ApoC3, an RNAi-Lipid Nanoparticle Therapeutic, Ameliorates Hypertriglyceridemia and Improves Metabolic Profile in Human-ApoC3 Transgenic Mice."
TKMR: 18.75 (-0.25)
Tekmira completes equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 10:57AM CDT
TKMR: 18.75 (-0.25)
Tekmira Announces Completion of Underwritten Public Offering of Common Shares
GlobeNewswire - Wed Mar 25, 10:24AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has completed its previously announced underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses. Tekmira also granted the underwriters a 30-day option to purchase up to an additional 1.125 million common shares, which, if exercised, would result in additional gross proceeds of US$22.8 million.
TKMR: 18.75 (-0.25)
Tekmira prices larger equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:36AM CDT
TKMR: 18.75 (-0.25)
Technical Briefing on Biotech Equities - Amgen, Exelixis, Sangamo BioSciences, Medivation, and Tekmira Pharma
PR Newswire - Fri Mar 20, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 131.01 (-1.50), SGMO: 14.70 (-0.84), TKMR: 18.75 (-0.25), AMGN: 167.91 (-1.26), EXEL: 3.08 (-0.02)
Tekmira Announces Pricing of Underwritten Public Offering of Common Shares
GlobeNewswire - Fri Mar 20, 8:00AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has priced an underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses.
TKMR: 18.75 (-0.25)
Tekmira initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:09PM CDT
TKMR: 18.75 (-0.25)
Tekmira Announces Proposed Public Offering of Common Shares
GlobeNewswire - Wed Mar 18, 3:01PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that the Company is offering to sell 6,000,000 common shares in an underwritten public offering. Tekmira also expects to grant the underwriters a 30‐day option to purchase up to an additional 900,000 common shares.
TKMR: 18.75 (-0.25)
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 18, 1:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PRSC: 49.35 (+0.02), GLMD: 9.14 (-0.72), CERU: 6.27 (+0.07), AKRX: 55.24 (-0.68), ADHD: 5.90 (+0.07), TKMR: 18.75 (-0.25), BIND: 6.84 (-0.33), UG: 19.21 (+1.00), TKM.TO: 22.97 (+0.52), AVID: 16.15 (-0.20), OREX: 7.36 (-0.08), AFMD: 11.72 (+3.47), BDE: 9.05 (-0.20), VTSS: 5.27 (-0.01), RTRX: 24.75 (+0.01), REPH: 11.88 (+1.04)
Tekmira Strengthens Senior Leadership Team With Key Executive Appointments in Corporate Affairs, Chemistry and Biology
GlobeNewswire - Wed Mar 18, 7:15AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced three executive appointments: Adam Cutler has been appointed Senior Vice President, Corporate Affairs; Dr. Bruce Dorsey has been appointed Vice President, Chemistry; and Dr. Rene Cornelis Rijnbrand has been appointed Vice President, Biology. Each of these executives brings to Tekmira broad biopharmaceutical industry experience and a track record of success, with complementary skills and talents that strengthen the Company's senior leadership team.
TKMR: 18.75 (-0.25)
Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results
GlobeNewswire - Wed Apr 22, 6:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), announced that it will hold a conference call and webcast on Wednesday, May 6, 2015 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and first quarter financial results.
TKMR: 18.75 (-0.25)
Tekmira Pharmaceuticals'
at Investor's Business Daily - Wed Apr 22, 5:48PM CDT
Tekmira Pharmaceuticals' (TKMR) Ebola-fighting drug, in a recent test, cured 3 monkeys infected with the strain of the virus that has devastated W. Africa over the past year, Reuters reported. Shares fell 0.8% to 18.38.
TKMR: 18.75 (-0.25)
Tekmira and Collaborators Publish Positive Preclinical Ebola Survival Data in Nature Journal
GlobeNewswire - Wed Apr 22, 1:13PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today the publication of preclinical data highlighting positive results against Ebola virus Makona infection using a newly adjusted siRNA cocktail. The paper is titled, "Lipid Nanoparticle siRNA Treatment of Ebola Virus Makona-infected Nonhuman Primates," (Thi et al., Nature April 22, 2015, doi:10.1038/nature14442).
TKMR: 18.75 (-0.25)
Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 15, 2:15PM CDT
The Medicines Co. (MDCO) was in the limelight with the company gearing up for an FDA advisory panel meeting.
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), GWPH: 121.00 (+0.23), MDCO: 27.41 (+0.09), ALXN: 180.08 (-4.50), TKMR: 18.75 (-0.25), AMGN: 167.91 (-1.26)
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 10:10AM CDT
The FDA has notified Tekmira (TKMR) that it has modified the partial clinical hold on the IND for TKM-Ebola.
SRPT: 13.42 (-0.24), TKMR: 18.75 (-0.25), GSK: 46.59 (+0.28), ACOR: 33.12 (-0.38)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 401.71 (-28.57), SPHS: 0.80 (-0.03), ADMS: 17.70 (-0.03), TKMR: 18.75 (-0.25), CBYL: 7.45 (-0.11), HPTX: 45.97 (-0.11), QURE: 26.09 (-0.28), SHPG: 255.11 (-0.26), SRPT: 13.42 (-0.24), HZNP: 31.75 (+0.97), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), ABBV: 66.07 (+1.82), CBMG: 29.51 (-1.85), ARNA: 4.49 (+0.05), EXEL: 3.08 (-0.02), ADXS: 23.34 (-0.27), PTLA: 38.51 (-0.85), BMY: 65.80 (-0.20), OCUL: 25.36 (-1.12), NVO: 56.65 (+0.44), DVA: 83.91 (+0.50), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), ALXN: 180.08 (-4.50), NVS: 104.28 (-1.22)
Tekmira will resume safety study of Ebola drug within weeks
AP - Fri Apr 10, 10:46AM CDT
NEW YORK (AP) — Canadian drugmaker Tekmira Pharmaceuticals said Friday it will restart a study of an experimental Ebola treatment in the coming weeks.
TKMR: 18.75 (-0.25), TKM.TO: 22.97 (+0.52)
Tekmira's Ebola vaccine candidate cleared for repeat dosing in Phase 1 study
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 8:45AM CDT
TKMR: 18.75 (-0.25)
FDA Modifies Partial Clinical Hold on Tekmira's TKM-Ebola IND to Allow Multiple Dosing of Healthy Volunteers
GlobeNewswire - Fri Apr 10, 7:30AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that the partial clinical hold on the company's Investigational New Drug application (IND) for TKM-Ebola has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day. The IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers.
TKMR: 18.75 (-0.25)
Tekmira Presents Preclinical Results Demonstrating Super-Additive Effects on Plasma Triglyceride Lowering by Silencing of ApoC3 and ANGPTL3 Genes
GlobeNewswire - Wed Mar 25, 6:30PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that new preclinical data on TKM-HTG, an RNAi therapeutic, were presented at the Keystone Symposia Conference: Liver Metabolism and Nonalchoholic Fatty Liver Diseases, in Whistler, Canada, March 22-27, 2015. Dr. Narayanan Hariharan, Senior Director of Research for Tekmira, delivered a podium presentation at the conference titled, "Novel RNAi-Lipid Nanoparticle Therapeutics for Hypertriglyceridemia," and a poster presentation titled, "TKM-ApoC3, an RNAi-Lipid Nanoparticle Therapeutic, Ameliorates Hypertriglyceridemia and Improves Metabolic Profile in Human-ApoC3 Transgenic Mice."
TKMR: 18.75 (-0.25)
Tekmira completes equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 10:57AM CDT
TKMR: 18.75 (-0.25)
Tekmira Announces Completion of Underwritten Public Offering of Common Shares
GlobeNewswire - Wed Mar 25, 10:24AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has completed its previously announced underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses. Tekmira also granted the underwriters a 30-day option to purchase up to an additional 1.125 million common shares, which, if exercised, would result in additional gross proceeds of US$22.8 million.
TKMR: 18.75 (-0.25)
Tekmira prices larger equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:36AM CDT
TKMR: 18.75 (-0.25)
Technical Briefing on Biotech Equities - Amgen, Exelixis, Sangamo BioSciences, Medivation, and Tekmira Pharma
PR Newswire - Fri Mar 20, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MDVN: 131.01 (-1.50), SGMO: 14.70 (-0.84), TKMR: 18.75 (-0.25), AMGN: 167.91 (-1.26), EXEL: 3.08 (-0.02)
Tekmira Announces Pricing of Underwritten Public Offering of Common Shares
GlobeNewswire - Fri Mar 20, 8:00AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that it has priced an underwritten public offering of 7.5 million common shares at a price of US$20.25 per share for aggregate gross proceeds of US$151.9 million before deducting underwriting discounts and commissions and other offering expenses.
TKMR: 18.75 (-0.25)
Tekmira initiates equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 3:09PM CDT
TKMR: 18.75 (-0.25)
Tekmira Announces Proposed Public Offering of Common Shares
GlobeNewswire - Wed Mar 18, 3:01PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), announced today that the Company is offering to sell 6,000,000 common shares in an underwritten public offering. Tekmira also expects to grant the underwriters a 30‐day option to purchase up to an additional 900,000 common shares.
TKMR: 18.75 (-0.25)
Nasdaq stocks posting largest percentage increases
AP - Wed Mar 18, 1:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PRSC: 49.35 (+0.02), GLMD: 9.14 (-0.72), CERU: 6.27 (+0.07), AKRX: 55.24 (-0.68), ADHD: 5.90 (+0.07), TKMR: 18.75 (-0.25), BIND: 6.84 (-0.33), UG: 19.21 (+1.00), TKM.TO: 22.97 (+0.52), AVID: 16.15 (-0.20), OREX: 7.36 (-0.08), AFMD: 11.72 (+3.47), BDE: 9.05 (-0.20), VTSS: 5.27 (-0.01), RTRX: 24.75 (+0.01), REPH: 11.88 (+1.04)
Tekmira Strengthens Senior Leadership Team With Key Executive Appointments in Corporate Affairs, Chemistry and Biology
GlobeNewswire - Wed Mar 18, 7:15AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced three executive appointments: Adam Cutler has been appointed Senior Vice President, Corporate Affairs; Dr. Bruce Dorsey has been appointed Vice President, Chemistry; and Dr. Rene Cornelis Rijnbrand has been appointed Vice President, Biology. Each of these executives brings to Tekmira broad biopharmaceutical industry experience and a track record of success, with complementary skills and talents that strengthen the Company's senior leadership team.
TKMR: 18.75 (-0.25)
